Arch Therapeutics Inc (ARTH)

[Polyphemus]

GrosPied I am confident that ARTH submitted a 510(k) for a topical wound dressing using the AC5 technbology (see SEC filing), and that it will submit an application for a similar indication for use to obtain a CE mark. This type of device/indication for use is a far cry from a hemostat for surgical use. Big market, but much less value than original discussion.

Big question arises now: how many of these wound dressings will ARTH sell and at what price/gross margin? They will needs one or more distributors to make any impact; any announcmenets on this topic?

Future development of AC5 into something meaningful now depends on commercial success of AC5 wound dressing in a very crowded and price sensitive field. If ARTH delays commercialization, that could be read as an ominous sign.